Sandbox Reserved 712: Difference between revisions
From Proteopedia
Jump to navigationJump to search
| Line 18: | Line 18: | ||
3ggu (also PR<sub>DRV5</sub>) is a mutated clinically derived PR that shows phenotypical resistance to darunavir. Darunavir is a human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) which has inhibiting effects on many HIV type 1 PR variants that show resistance to earlier-generation-PIs. <ref name="Molecular"> PMID:19535439 </ref> | 3ggu (also PR<sub>DRV5</sub>) is a mutated clinically derived PR that shows phenotypical resistance to darunavir. Darunavir is a human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) which has inhibiting effects on many HIV type 1 PR variants that show resistance to earlier-generation-PIs. <ref name="Molecular"> PMID:19535439 </ref> | ||
== '''Darunavir | == '''Darunavir: HIV-Protease Inhibitor''' == | ||
Darunavir (also known as TMC114) is a HIV-PR Inhibitor. The wild-type HIV as well as a large penal of PI-resistant recombinant viruses derived from clinical samples show high susceptibility to darunavir. <ref> PMID:15917527 </ref> | Darunavir (also known as TMC114) is a HIV-PR Inhibitor. The wild-type HIV as well as a large penal of PI-resistant recombinant viruses derived from clinical samples show high susceptibility to darunavir. <ref> PMID:15917527 </ref> | ||
